Literature DB >> 35028946

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety.

Hanyan Meng1, Jianhua Mao1, Qing Ye2.   

Abstract

At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; booster vaccination; heterologous vaccination; vaccine

Mesh:

Substances:

Year:  2022        PMID: 35028946     DOI: 10.1002/jmv.27590

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  Accurate Interpretation of SARS-CoV-2 Antigen Detection by Immunochromatography.

Authors:  Wenxia Shao
Journal:  Front Med (Lausanne)       Date:  2022-06-29

Review 2.  Performance and application evaluation of SARS-CoV-2 antigen assay.

Authors:  Qing Ye; Wenxia Shao; Hanyan Meng
Journal:  J Med Virol       Date:  2022-04-30       Impact factor: 20.693

3.  A single-center COVID-19 vaccine experience with CoronaVac and BNT162b2 in familial Mediterranean fever patients.

Authors:  Serdar Can Güven; Özlem Karakaş; Ebru Atalar; Hatice Ecem Konak; Pınar Akyüz Dağlı; Esra Kayacan Erdoğan; Berkan Armağan; Kevser Gök; İsmail Doğan; Yüksel Maraş; Abdulsamet Erden; Şükran Erten; Orhan Küçükşahin; Ahmet Omma
Journal:  Int J Rheum Dis       Date:  2022-06-01       Impact factor: 2.558

4.  Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers.

Authors:  Sabina Zurac; Cristian Vladan; Octavian Dinca; Carolina Constantin; Monica Neagu
Journal:  Sci Rep       Date:  2022-07-26       Impact factor: 4.996

5.  COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups.

Authors:  Sherrie L Kelly; Epke A Le Rutte; Maximilian Richter; Melissa A Penny; Andrew J Shattock
Journal:  Infect Dis Ther       Date:  2022-09-12

6.  Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients.

Authors:  Dániel Honfi; Nikolett Gémes; Enikő Szabó; Patrícia Neuperger; József Á Balog; Lajos I Nagy; Gergely Toldi; László G Puskás; Gábor J Szebeni; Attila Balog
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.